Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Safety and antitumor activity of recombinant soluble Apo2 ligand.

Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH.

J Clin Invest. 1999 Jul;104(2):155-62.

2.

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.

Jin H, Yang R, Fong S, Totpal K, Lawrence D, Zheng Z, Ross J, Koeppen H, Schwall R, Ashkenazi A.

Cancer Res. 2004 Jul 15;64(14):4900-5.

3.

Apo2l/Tumor necrosis factor-related apoptosis-inducing ligand prevents breast cancer-induced bone destruction in a mouse model.

Thai le M, Labrinidis A, Hay S, Liapis V, Bouralexis S, Welldon K, Coventry BJ, Findlay DM, Evdokiou A.

Cancer Res. 2006 May 15;66(10):5363-70.

4.
5.
6.
10.

Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.

Qin JZ, Bacon PE, Chaturvedi V, Bonish B, Nickoloff BJ.

Exp Dermatol. 2002 Dec;11(6):573-83.

PMID:
12473065
11.

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications.

Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC.

Blood. 2001 Aug 1;98(3):795-804.

12.

IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.

Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC.

J Immunol. 2002 Jul 15;169(2):847-55.

13.

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

Roth W, Isenmann S, Naumann U, Kügler S, Bähr M, Dichgans J, Ashkenazi A, Weller M.

Biochem Biophys Res Commun. 1999 Nov 19;265(2):479-83.

PMID:
10558893
14.

Concepts in the use of TRAIL/Apo2L: an emerging biotherapy for myeloma and other neoplasias.

Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP.

Expert Opin Investig Drugs. 2001 Aug;10(8):1521-30.

PMID:
11772267
16.
17.

The potential of the tumor microenvironment to influence Apo2L/TRAIL induced apoptosis.

Mace TA, Yamane N, Cheng J, Hylander BL, Repasky EA.

Immunol Invest. 2006;35(3-4):279-96. Review.

PMID:
16916755
18.

Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.

Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.

Cancer Res. 2006 Jun 1;66(11):5867-74.

20.

Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.

Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC.

Cancer Res. 2005 Jun 1;65(11):4799-808.

Supplemental Content

Support Center